Clinical Trials Logo

Clinical Trial Summary

The research question is whether a single fraction of preoperative radiosurgery can reduce the incidence of leptomeningeal disease 12 months following resection of a brain metastasis (BM) as compared with 5 fractions of postoperative stereotactic radiotherapy.

Clinical Trial Description

Neurosurgical resection of a brain metastasis in patients with a diagnosis of cancer may be indicated however the recurrence rate approximates 50% and adjuvant radiotherapy is standard. Single fraction postoperative stereotactic radiosurgery (SRS) has been widely adopted as a standard therapy as it achieves equivalent survival and prevents loss of neurocognitive function as compared with whole brain radiotherapy and improves cavity local control rates as compared with observation. Hypofractionated stereotactic radiotherapy in 3 to 5 fractions (hfSRT) is also used in the postoperative setting. Nodular leptomeningeal disease (nLMD) is a recognised pattern of failure after postoperative SRS and hfSRT. A 16.9% incidence of nodular LMD was seen after surgery and a similar incidence of 11%-28%is reported following postoperative SRS in retrospective series. These data suggest that postoperative SRS/hfSRT have no significant effect on the development of LMD following surgery. The incidence of LMD following single fraction preoperative SRS is only 6.1% according to the largest retrospective series. Preoperative SRS takes advantage of the easier delineation of an intact BM and sterilizes tumor cells disseminated at surgery. Side effects are minimized by a smaller planning margin, a dose reduction and resection of the irradiated volume. In addition, there is no delay to systemic therapy due to wound healing/complications. Furthermore, a single fraction offers patient convenience. This trial will randomise and compare intracranial outcomes between single fraction preoperative SRS and 5 fraction postoperative hFSRT. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05124236
Study type Interventional
Source Kantonsspital Aarau
Status Not yet recruiting
Phase N/A
Start date January 1, 2022
Completion date December 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04397978 - Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
Terminated NCT04434560 - Neoadjuvant Immunotherapy in Brain Metastases Phase 2
Recruiting NCT05095766 - Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
Not yet recruiting NCT04197297 - Brain Imaging Biomarkers in Patients With Brain Metastasis Phase 2
Not yet recruiting NCT05087095 - Managing Distress in Malignant Brain Cancer N/A
Not yet recruiting NCT05050929 - RAPid SimPLE Targeted Radiation Treatment for Brain Metastases Phase 2/Phase 3
Completed NCT03896555 - Intrafractional Head Movement During Radiosurgery
Active, not recruiting NCT03789149 - Focal Intraoperative Radiotherapy of Brain Metastases Phase 2
Completed NCT02886572 - SIMT Stereotactic Radiosurgery Outcomes Study N/A
Recruiting NCT04343157 - UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases Phase 2
Recruiting NCT04461418 - Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases Phase 2
Recruiting NCT03818386 - Radiotherapy of Multiple Brain Metastases Using AGuIX® Phase 2
Recruiting NCT04396717 - Safety Study of Pritumumab in Brain Cancer Phase 1
Active, not recruiting NCT02978404 - Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases Phase 2
Recruiting NCT04075370 - Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer
Recruiting NCT05126875 - Re-TREAT: Re-irradiation for Relapsed Brain Metastases N/A
Recruiting NCT04785521 - Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery
Recruiting NCT03561896 - Hypofractionated Brain Radiationcavity N/A
Recruiting NCT04187872 - LITT and Pembrolizumab in Recurrent Brain Metastasis Phase 1
Not yet recruiting NCT04711824 - Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases Phase 1/Phase 2